Levoflox

# levoflox ## Overview - **Classification**: Fluoroquinolone Antibiotic - **Mechanism**: Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, essential enzymes for DNA replication, transcription, repair, and recombination, leading to bacterial cell death. ## Primary Indications 1. **Community-Acquired Pneumonia (CAP)** - Treatment of adult patients 2. **Acute Bacterial Sinusitis (ABS)** - Treatment of adult patients 3. **Complicated Urinary Tract Infections (cUTI) & Pyelonephritis** - Treatment of adult and selected pediatric patients 4. **Chronic Bacterial Prostatitis** - Treatment of adult patients 5. **Skin and Skin Structure Infections (uncomplicated & complicated)** - Treatment of adult patients 6. **Anthrax (inhalation, post-exposure)** - Prophylaxis and treatment in adults and pediatric patients 7. **Plague** - Treatment in adults and pediatric patients ## Adult Dosing ### Standard Dosing **Community-Acquired Pneumonia (CAP), Acute Bacterial Sinusitis (ABS), Chronic Bacterial Bronchitis (AECB)** - **Dose**: **500 mg** - **Frequency**: Once daily (QD) - **Route**: PO or IV - **Duration**: 7-14 days (CAP/AECB), 10-14 days (ABS) **Severe Community-Acquired Pneumonia (CAP), Complicated Skin & Skin Structure Infections (cSSSI)** - **Dose**: **750 mg** - **Frequency**: Once daily (QD) - **Route**: PO or IV - **Duration**: 5 days (CAP), 7-14 days (cSSSI) **Complicated Urinary Tract Infections (cUTI), Pyelonephritis** - **Dose**: **250 mg** or **500 mg** - **Frequency**: Once daily (QD) - **Route**: PO or IV - **Duration**: 5 days (cUTI), 5-10 days (Pyelonephritis) **Chronic Bacterial Prostatitis** - **Dose**: **500 mg** - **Frequency**: Once daily (QD) - **Route**: PO or IV - **Duration**: 28 days ### Dose Adjustments - **Renal Impairment**: Adjust based on CrCl - CrCl **20-49 mL/min**: Initial **750 mg**, then **250 mg** Q24hr. Or, initial **500 mg**, then **250 mg** Q24hr. - CrCl **10-19 mL/min**: Initial **750 mg**, then **250 mg** Q48hr. Or, initial **500 mg**, then **125 mg** Q24hr. - CrCl **<10 mL/min (including HD/CAPD)**: Initial **750 mg**, then **250 mg** Q48hr. Or, initial **500 mg**, then **125 mg** Q24hr. Administer after dialysis on dialysis days. - **Hepatic Impairment**: No specific dose adjustment necessary. - **Elderly Patients**: Monitor renal function closely as age increases risk of renal impairment. Increased risk of tendon rupture and QTc prolongation. ## Pediatric Dosing *(Use in pediatric patients is generally limited to specific severe infections where benefits outweigh risks, due to risk of musculoskeletal adverse events.)* ### Neonates (0-28 days) - **Dose**: Generally **NOT recommended**. If used for severe indications (e.g., anthrax, plague) with extreme caution: **5 mg/kg** - **Frequency**: Every 12 hours (Q12hr) - **Maximum**: **250 mg/dose** - **Special Notes**: Consider ECG monitoring due to QTc prolongation risk in this population. ### Infants (1-12 months) - **Dose**: Generally **NOT recommended**. For severe indications: **10 mg/kg** - **Frequency**: Every 12 hours (Q12hr) - **Maximum**: **250 mg/dose** - **Special Notes**: Risk of arthropathy. Carefully weigh risks vs. benefits. ### Children (1-12 years) - **Indication (Anthrax/Plague)**: **10-15 mg/kg** - **Frequency**: Every 12 hours (Q12hr) - **Maximum**: **500 mg/dose** or **1000 mg/day** (Anthrax), **250 mg/dose** (Plague) - **Indication (Complicated UTI/Pyelonephritis - when alternatives unavailable)**: **10 mg/kg** - **Frequency**: Every 24 hours (Q24hr) - **Maximum**: **500 mg/day** - **Special Notes**: Oral solution (25 mg/mL) or tablets can be used. Risk of arthropathy. ### Adolescents (13-18 years) - **Dose**: Generally follows adult dosing based on weight and indication. - **Maximum**: Adult maximum dose for the specific indication. - **Special Notes**: Monitor for tendon pain, as risk of tendon rupture may still be present. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to levofloxacin or other fluoroquinolones. - **Absolute**: History of tendon disorders related to quinolone administration. - **Absolute**: Myasthenia Gravis (may exacerbate muscle weakness). ### Common Adverse Effects - **Common (1-10%)**: Nausea, Diarrhea, Headache, Insomnia, Constipation. - **Serious but Rare**: - **Tendinitis and Tendon Rupture**: Especially Achilles tendon. Can occur during or after treatment. - **Peripheral Neuropathy**: May be irreversible. Symptoms include pain, burning, tingling, numbness. - **Central Nervous System Effects**: Seizures, psychosis, tremors, confusion, hallucinations. - **QTc Prolongation and Torsades de Pointes**: Increased risk with pre-existing QTc prolongation, hypokalemia/hypomagnesemia, or concomitant drugs. - **Aortic Aneurysm Rupture/Dissection**: Increased risk, especially in elderly and those with risk factors. - **Hypo/Hyperglycemia**: Especially in diabetic patients. - **Clostridioides difficile-associated diarrhea (CDAD)**: Can range from mild diarrhea to fatal colitis. - **Hypersensitivity Reactions**: Anaphylaxis, Stevens-Johnson syndrome, Toxic Epidermal Necrolysis. - **Photosensitivity**: Severe sunburn reaction. ### Key Drug Interactions - **Multivalent Cations (Antacids, Sucralfate, Iron, Zinc, Mg/Al supplements)**: Significantly decrease levofloxacin absorption. Administer levofloxacin at least **2 hours before or 2 hours after** these agents. - **Warfarin**: May enhance anticoagulant effect. Monitor **INR** closely. - **Antiarrhythmics (Class IA & III), TCAs, Macrolides, Antipsychotics**: Additive QTc prolongation risk. Avoid co-administration if possible. - **NSAIDs**: May increase risk of CNS stimulation and seizures. Use with caution. - **Sulfonylureas/Insulin**: May cause dysglycemia (hypoglycemia or hyperglycemia). Monitor **blood glucose** closely. ## Monitoring & Follow-up - **Before Treatment**: - Renal function (CrCl) to guide dosing. - Electrolytes (K, Mg) if risk for QTc prolongation. - ECG if cardiac risk factors for QTc prolongation are present. - **During Treatment**: - Monitor for signs of tendon pain/inflammation, peripheral neuropathy (pain, burning, tingling, numbness). - Monitor blood glucose in diabetic patients. - Observe for CNS effects (seizures, confusion). - Assess for severe or persistent diarrhea (C. difficile). - Monitor for signs of allergic reaction or severe skin rash. - **Clinical Signs**: Report any joint pain, swelling, numbness, tingling, weakness, confusion, palpitations, or severe diarrhea immediately. ## Clinical Pearls - 💡 **Black Box Warning**: FDA-mandated for serious adverse events: Tendinitis/rupture, Peripheral neuropathy, CNS effects, and exacerbated Myasthenia Gravis. Reserve use for situations where benefits outweigh risks. - 💡 **Administration**: Can be taken with or without food. Take with a full glass of water. Avoid dairy products or calcium-fortified juices **2 hours before or 2 hours after** levofloxacin. - 💡 **Photosensitivity**: Advise patients to use sun protection and avoid excessive sun exposure. - 💡 **Complete Course**: Emphasize importance of completing the entire prescribed course, even if symptoms improve, to prevent resistance. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.